Showing results (191-200 of 437) with videos related to

Sort By:
Pageof 44
The Journal of Biological Chemistry|April 8, 2015
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer TherapyRama K Mishra, Changyong Wei, Richard C Hresko, et al.
JCO Oncology Practice|May 30, 2020
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United StatesYang Yu, Niquelle Brown Wade, Amie E Hwang, et al.
Blood Cancer Discovery|December 13, 2022
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough InfectionsMaryam I Azeem, Ajay K Nooka, Uma Shanmugasundaram, et al.
Expert Review of Hematology|January 12, 2017
Deacetylase inhibitors: an advance in myeloma therapy?Jacob P Laubach, Jesus F San-Miguel, Vania Hungria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 SignalingJie Li, Chaoyun Pan, Austin C Boese, et al.
Research Square|April 1, 2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA VaccinationFrances Lee, Doan Nguyen, Ian Hentenaar, et al.
Blood|April 10, 2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cellsYanyan Gu, Jonathan L Kaufman, Leon Bernal, et al.
Transfusion|September 3, 2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trialNeera Jagirdar, R Donald Harvey, Ajay Nooka, et al.
Expert Opinion on Pharmacotherapy|November 14, 2018
Ixazomib for the treatment of multiple myelomaPaul G Richardson, Sonja Zweegman, Elizabeth K O'Donnell, et al.
Blood|September 17, 2010
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomesEbenezer David, Jonathan L Kaufman, Christopher R Flowers, et al.
Pageof 44